Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02833506
Title Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Withdrawn
Gender female
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute

fallopian tube carcinoma

peritoneal carcinoma

ovary epithelial cancer


NY-ESO-1 peptide vaccine + Sirolimus

NY-ESO-1 peptide vaccine

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.